Global Cystic Fibrosis Market Report 2022-2030 - Expanding Therapeutic Options is Expected to Drive Market Growth
August 03, 2022 08:03 ET
|
Research and Markets
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
First Wave BioPharma, Inc. Announces Private Placement
July 15, 2022 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis
June 15, 2022 07:30 ET
|
Aceragen
RALEIGH-DURHAM, NC , June 15, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing therapies for rare pulmonary and rheumatic diseases with high unmet...
$179.34 Million by 2028, OPEP (Oscillating Positive Expiratory Pressure) Devices Market, 5.2% CAGR Lead by Mouthpiece PEP Devices - Exclusive Research Report by The Insight Partners
May 10, 2022 04:13 ET
|
The Insight Partners
New York, May 10, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Oscillating Positive Expiratory Pressure (OPEP) Devices Market Forecast to 2028 – COVID-19 Impact...
Fecal Pancreatic Elastase Testing Market Is Set to Expand at A CAGR Of 7.7% To Reach US$ 30.2 Million By the Year 2032: FMI
April 20, 2022 11:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
Companies Profiled in Fecal Pancreatic Elastase Testing Market are Laboratory Corporation of America® Holdings, DiaSorin, ScheBo Biotech AG, Immundiagnostik AG, Invivo Healthcare, DRG Instruments...
First Wave BioPharma to Participate in Maxim’s 2022 Virtual Growth Conference
March 22, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Appointment of Sarah Romano as Chief Financial Officer
March 01, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 01, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference
February 07, 2022 07:30 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Cystic Fibrosis Pipeline Offers Promising New Options for Treatment | DelveInsight
January 26, 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cystic Fibrosis Pipeline Offers Promising New Options for Treatment | DelveInsight The Cystic Fibrosis (CF) therapeutic development pipeline...
First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program
January 13, 2022 07:00 ET
|
First Wave BioPharma, Inc.
Company filed two provisional patent applications for new enteric granule formulation of adrulipase and for related nutritional indications in new patient populations “Adrulipase Alfa” approved by...